A Year of Vision: How ENCELTO is Changing the Game for a Rare Eye Disease

CUMBERLAND, RI – March 12, 2026 – By Debra Allen

One year ago, the landscape for patients with Macular Telangiectasia Type 2 (MacTel), a rare and progressive neurodegenerative disease, was bleak. With no approved treatments, those diagnosed faced a gradual and irreversible loss of central vision. Today, the story is being rewritten. Neurotech Pharmaceuticals, Inc., a private biotech firm, is marking the first anniversary of the FDA’s approval of ENCELTO™ (taroretcel-lwey), a first-in-class encapsulated cell-based gene therapy, and the update reveals a company successfully transitioning from clinical development to commercial reality.

In just twelve months, the therapy has seen significant uptake. More than 700 patients have been enrolled in the ENCELTOconnect patient portal, and retina surgeons nationwide have performed over 100 implant procedures. This milestone, which includes patients receiving implants in their second eye, signals growing confidence within the specialized medical community for a treatment that was, until recently, just a clinical trial concept.

“Since approval, our focus has been disciplined execution, responsible integration, and strong partnership with the retina community,” said Richard Small, Chief Executive Officer of Neurotech Pharmaceuticals, in a statement. “We are encouraged by how clinicians are incorporating this therapy into practice and by the continued progress in access, and clinical adoption.”

A New Dawn for MacTel Patients

MacTel Type 2 is insidious. It typically affects adults over 40, causing the gradual deterioration of photoreceptors—the light-sensing cells in the macula, the part of the retina responsible for sharp, detailed central vision. This leads to difficulty reading, recognizing faces, and driving, profoundly impacting a person's independence and quality of life. With a prevalence estimated between 0.0045% and 0.1% in various populations, it is a rare disease, but for those affected, the impact is immense.

ENCELTO represents a paradigm shift. The therapy is not a pill or an injection, but a tiny, rice-sized implant surgically placed inside the eye during an outpatient procedure. This capsule contains genetically engineered living cells programmed to continuously produce a therapeutic protein called ciliary neurotrophic factor (CNTF). The implant's semi-permeable membrane allows the CNTF to diffuse into the eye and reach the retina, where it helps protect photoreceptors from dying, thereby slowing the disease's progression. The capsule also shields the internal cells from the patient's immune system, allowing for long-term, sustained delivery of the therapy from a single procedure.

For patients, this means a move away from managing inevitable decline to actively preserving vision. Clinical trial participants have reported meaningful improvements in their vision-related quality of life, with some, like a 58-year-old architect from a study, highlighting the therapy's role in preserving their career and independence.

Navigating the Complex Path to Market

Bringing a revolutionary, high-cost gene therapy to market is a monumental challenge, but Neurotech’s one-year update provides a blueprint for success. A key achievement has been navigating the intricate world of healthcare reimbursement. The company secured a permanent J-Code (J3403) for ENCELTO, which took effect on October 1, 2025. This code is a critical piece of infrastructure, streamlining the billing and payment process for both government payers like Medicare and commercial insurers.

The results speak for themselves: 88 medical policies have been established, creating pathways to access for approximately 200 million covered lives. Major insurers like Aetna and UnitedHealthcare have developed coverage policies, albeit with specific criteria, such as evidence of photoreceptor damage and a certain level of remaining visual acuity. This widespread payer acceptance is crucial for ensuring that the therapy is not just a scientific marvel but a practical option for eligible patients across diverse practice settings.

Despite this progress, hurdles remain. The therapy requires a vitreoretinal surgeon with specific expertise, and billing for high-cost treatments in outpatient settings like Ambulatory Surgical Centers (ASCs) can still involve complexities. However, Neurotech’s focus on building partnerships with the retina community and providing robust patient support through programs like ENCELTOconnect appears to be effectively managing these challenges.

The Science of Sustained Delivery: Efficacy and Safety

The commercial success of ENCELTO is built on a foundation of robust scientific evidence. The FDA approval was based on data from two pivotal Phase 3 clinical trials, known as the MARIGOLD studies. The results were compelling: over 24 months, ENCELTO-treated eyes showed a statistically significant slowing of photoreceptor loss compared to sham-treated eyes. In one trial, the rate of loss was reduced by 54.8%, and in the other, by 30.6%. This anatomical preservation was also linked to a slowing of functional vision loss in some measures.

Perhaps most remarkably, the underlying Encapsulated Cell Therapy (ECT) platform has demonstrated incredible durability. Research on devices explanted from patients in earlier studies showed that some were still producing therapeutic levels of CNTF after more than 14 years, suggesting the potential for a very long-term effect from a single implant.

As with any medical intervention, benefits must be weighed against risks. ENCELTO was generally well-tolerated in trials, though the surgical procedure and the implant itself carry potential side effects. The most common issues reported were relatively minor, such as eye redness, irritation, and the sensation of a foreign object. More significant was the side effect of delayed dark adaptation—a slower adjustment of vision when moving from bright to dark environments—which requires patients to take extra precautions, such as when driving into a tunnel. Serious but rare adverse events, including suture complications and implant extrusion, occurred in a small percentage of patients. To date, no study participant has required removal of the implant due to side effects, a testament to its general tolerability.

Beyond MacTel: The Future of Encapsulated Cell Therapy

While ENCELTO is a triumph for the MacTel community, its greatest long-term significance may be as a proof-of-concept for Neurotech's entire ECT platform. The successful commercialization validates the approach of using a protected, implantable cell factory to provide sustained, localized drug delivery for chronic eye diseases.

This success has reinvigorated the platform's potential. While previous attempts to gain approval for ECT in other conditions like retinitis pigmentosa did not succeed, the validation from ENCELTO has opened new doors. Researchers are now actively investigating the platform's application for other major eye diseases that are leading causes of blindness, including glaucoma and age-related macular degeneration.

For Neurotech, a private company that has methodically advanced its technology for years, the first anniversary of ENCELTO is more than a milestone. It marks the arrival of a new therapeutic modality and a beacon of hope, not just for those with MacTel, but potentially for millions more suffering from chronic, sight-threatening diseases.